secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2026-06-26T12:14:23+00:00
Accession:  0001104659-26-078009
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts Replimune's BLA resubmission for RP1 in advanced melanoma; decision by Aug 2
--------------------------------------------------------------------------------

- FDA accepted as complete, class 1 response; PDUFA goal date August 2, 2026.
- Advisory committee meeting expected in late July 2026.
- Resubmission based on Phase 2 IGNYTE trial data for RP1 + nivolumab in anti-PD-1 progressed patients.
- RP1 (vusolimogene oderparepvec) seeks accelerated approval for advanced melanoma.
- CEO notes FDA urgency reflecting significant unmet need and community support.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465926078009/0001104659-26-078009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465926078009/tm2619037d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-078009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer